An experimental anti-clotting medication, abelacimab, significantly reduced bleeding among people with atrial fibrillation (or AFib) who were at risk of stroke, according to results of the AZALEA-TIMI 71 trial, presented today as late-breaking science at the American Heart Association’s Scientific Sessions 2023.